Stay up-to-date with the latest developments in gene and cell therapy by subscribing to our newsletter.
Featured:
Jul 09 | CoRegen Secures $93M to Advance Novel Treg Cell Therapies into Clinic read more »
Jul 08 | Chan Zuckerberg Initiative Launches Center for Personalized CRISPR Cures for Rare Pediatric Diseases read more »
Jul 07 | JCR Pharmaceuticals Licenses Proprietary JUST-AAV Capsid Platform to Alexion for Genomic Medicines in Deal Valued Up To $825 Million read more »
News:
Jul 10 | Klotho Neurosciences Receives FDA Orphan Drug Designation for KLTO-202 in ALS read more »
Jul 08 | Centivax Secures $45M for Universal mRNA Flu Vaccine read more »
Jul 08 | Mustang Bio Receives FDA Orphan Drug Designation for MB-101 in Difficult-to-Treat Astrocytomas and Glioblastoma read more »
Jul 08 | Solid Biosciences’ SGT-501 AAV Gene Therapy Cleared for Clinical Trials! read more »
Jul 07 | Early Data for EsoBiotec’s In Vivo CAR-T Therapy (ESO-T01) in Multiple Myeloma read more »
Jul 07 | SCG Cell Therapy’s SCG101V Receives NMPA IND Clearance for Chronic Hepatitis B, First-Ever Cell Therapy for HBV read more »
Jul 07 | Lexeo Therapeutics Gains FDA Breakthrough Therapy Designation for AAV Gene Therapy in Friedreich Ataxia read more »
Articles:
Jul 09 | Synthetic efferocytic receptor microglia enhances anti-inflammatory clearance of amyloid-β for AD treatment in mice read more »
Jul 09 | High-throughput multiplexed gene and cell doping analysis through CRISPR-Cas12a system integrated with blood direct PCR read more »
Jul 09 | Targeted in vivo gene integration of a secretion-enabled GLP-1 receptor agonist reverses diet-induced non-genetic obesity and pre-diabetes read more »
Jul 08 | hafoe: an interactive tool for the analysis of chimeric AAV libraries after random mutagenesis read more »
Jul 07 | High-precision cytosine base editors by evolving nucleic-acid-recognition hotspots in deaminase read more »
Jul 07 | Immunogenicity of autologous and allogeneic human primary cholangiocyte organoid cellular therapies read more »
Jul 04 | Distinguishing Protein and Gene Delivery Enables Characterization and Bioengineering of Extracellular Vesicle-Adeno-Associated Virus Vectors read more »
Jul 04 | Bioengineered nanovesicles for efficient siRNA delivery through ligand-receptor-mediated and enzyme-controlled membrane fusion read more »
Jul 02 | In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma read more »
Jul 01 | Engineered microRNA scaffolds for potent gene silencing in vivo read more »
Jul 01 | Divergent antibody recognition profiles are generated by protective mRNA vaccines against Marburg and Ravn viruses read more »
Jul 01 | Budesonide-incorporated inhalable lipid nanoparticles for antiTSLP nanobody mRNA delivery to treat steroid-resistant asthma read more »
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
